Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
AZN : 78.58 (+0.06%)
GSK : 42.43 (-0.31%)
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

At its annual R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years.MRNA to Cut R&D Costs, Stops Five Pipeline ProgramsManagement...

SNY : 57.47 (+0.98%)
GSK : 42.43 (-0.31%)
MRK : 118.64 (+0.30%)
MRNA : 69.86 (-2.96%)
GSK's Respiratory Drug Nucala Meets Goal in COPD Study

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.Data from the...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
AZN : 78.58 (+0.06%)
GSK : 42.43 (-0.31%)
You Can Stop Looking, Here's the Perfect Stock for the Current Market

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over...

GSK : 42.43 (-0.31%)
HLN : 10.55 (-0.94%)
PFE : 29.75 (-0.27%)
JNJ : 166.15 (-0.55%)
KVUE : 23.19 (-0.86%)
SNY : 57.47 (+0.98%)
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Shares of Vaxcyte PCVX rose more than 36% on Tuesday after it reported positive top-line results from a phase I/II study on VAX-31, which is an investigational 31-valent pneumococcal conjugate vaccine...

GSK : 42.43 (-0.31%)
PFE : 29.75 (-0.27%)
MRK : 118.64 (+0.30%)
PCVX : 116.54 (-0.18%)
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has been approved...

GSK : 42.43 (-0.31%)
PFE : 29.75 (-0.27%)
ILMN : 130.97 (+0.58%)
MRNA : 69.86 (-2.96%)
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?

GSK GSK  stock has risen 18.5% so far this year compared with an increase of 27.1% for the industry. The stock has also been consistently trading above its 50-day and 200-day moving averages since mid-August.GSK...

GSK : 42.43 (-0.31%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
HLN : 10.55 (-0.94%)
Ozempic Medicare Negotiations Target Big Pharma in 2027

The anticipated 2027 Medicare drug negotiations are expected to impact several blockbuster drugs, with Novo Nordisk’s (NOVO) Ozempic, Pfizer’s (PFE) Ibrance and Xtandi, and GSK’s (GSK) Trelegy Ellipta...

PFE : 29.75 (-0.27%)
GSK : 42.43 (-0.31%)
TEVA : 17.88 (+0.17%)
ABBV : 192.94 (-0.26%)
Annovis Bio (NYSE: ANVS) Releases Promising Clinical Data As Alzheimer’s Therapeutics Market Grows

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.36 (-4.35%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
GSK : 42.43 (-0.31%)
NVO : 132.06 (+0.05%)
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033   

ANVS : 8.36 (-4.35%)
LLY : 904.97 (-0.13%)
GSK : 42.43 (-0.31%)
NVO : 132.06 (+0.05%)
PFE : 29.75 (-0.27%)

Barchart Exclusives

3 Top Dividend Stocks to Buy This September
After today's jumbo rate cut from the Fed, here are three dividend stocks to bolster your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar